Session IX: Hepatocellular Cancer

Chair(s)

• 

  Michel Ducreux, MD, PhD

  Gustave Roussy, Université Paris-Saclay
  Paris, France
• 

  Angela Lamarca, MD, PhD

  Fundacion Jimenez Diaz University Hospital
  Madrid, Spain

Presentations:

• 15:15 – 15:40 CEST

  Pathogenesis and Subtypes of HCC: NASH & Viral Etiology
  

  Speaker: Jessica Zucman-Rossi, MD, PhD – Université Paris Cité
• 15:40 – 16:00 CEST

  Diagnostic and Imaging Challenges in HCC
  

  Speaker: Jordi Rimola, MD PhD – Hospital Clínic Barcelona
• 16:00 – 16:08 CEST

  SO-14: Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup
  

  Abstract Presenter: Arndt Vogel, MD – Medizinische Hochschule Hannover
• 16:08 – 16:16 CEST

  SO-15: Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
  

  Abstract Presenter: Bruno Sangro, MD, PhD – Clinica Universidad de Navarra
• 16:16 – 16:24 CEST

  SO-16: Proton beam radiotherapy as a valid curative local alternative modality in newly diagnosed hepatocellular carcinoma: comparative study with radiofrequency ablation
  

  Abstract Presenter: Sang Hoon Seo
• 16:24 – 16:34 CEST

  Discussant: SO-14, SO-15, SO-16
  

  Discussant: Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital
• 16:34 – 16:55 CEST

  Are We Ready to Integrate Systemic Treatment in Early Stages of HCC
  

  Speaker: Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center
• 16:55 – 17:10 CEST

  How to Integrate and Sequence New Agents in Advanced HCC?
  

  Speaker: Lorenza Rimassa, MD – Humanitas University and IRCCS Humanitas Research Hospital
• 17:40 – 18:25 CEST

  Cases With Panel Discussion: Management Strategy in HCC: Locoregional Treatment vs Systemic Treatment
  

  Moderator: Angela Lamarca, MD, PhD – Fundacion Jimenez Diaz University Hospital

  Moderator: Lorenza Rimassa, MD – Humanitas University and IRCCS Humanitas Research Hospital

  Panelist: Arndt Vogel, MD – Medizinische Hochschule Hannover

  Panelist: Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center

  Panelist: Chris J. Verslype, MD PhD – University Hospitals Leuven / KU Leuven

  Panelist: Jordi Rimola, MD PhD – Hospital Clínic Barcelona